Key Takeaways AbbVie's neuroscience unit drove 17% of total sales in H1 2025 with 21% revenue growth.Botox, Vraylar, Qulipta and Ubrelvy boosted results, offsetting weaker Duodopa sales.Recent deals added MDD and Alzheimer's drug candidates to AbbVie's pipeline.AbbVie (ABBV) has built a robust neuroscience franchise over the years. Though the segment was initially heralded by blockbuster medications like Botox Therapeutic and the depression drug Vraylar, the company has significantly expanded its offerings ...